News

Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas

02/24/2026

Stephanie Holland

Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.

Results from the phase 2 LARA...

02/24/2026

Oncology

Conference Coverage

Using Pap-Derived ctDNA for Early Detection of Endometrial Cancer

06/05/2025

Alicia Latham, MD

Alicia Latham, MD, discusses results from a feasibility study which demonstrated the clinical promise of using pap-derived ctDNA to detect endometrial cancer.

Alicia Latham, MD, discusses...

06/05/2025

Oncology

Conference Coverage

Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer

06/03/2025

Emily Estrada

The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.

The addition of metformin to...

06/03/2025

Oncology

Conference Coverage

Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer

06/03/2025

Emily Estrada

The addition of metformin to...

06/03/2025

Oncology

Conference Coverage

Durvalumab With or Without Olaparib Plus Chemotherapy for Patients With Mismatch Repair Proficient Endometrial Cancer

03/19/2025

Allison Casey

Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...

Exploratory analyses from the...

03/19/2025

Oncology

Conference Coverage

Addition of Metformin to Letrozole and Abemaciclib Improves Response, PFS Among Patients With Recurrent Estrogen Receptor-Positive Endometrial Cancer

03/17/2025

Allison Casey

According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.

According to results from a...

03/17/2025

Oncology

Conference Coverage

Endometrial Sampling Among Patients Who Underwent Transvaginal Ultrasound for Postmenopausal Bleeding

03/17/2025

Allison Casey

A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.

A large multicenter study found...

03/17/2025

Oncology

News

Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer

12/18/2024

Stephanie Holland

Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...

Final results from the phase 3...

12/18/2024

Oncology

News

Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer

12/05/2024

Allison Casey

Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.

Chronic stress may be associated...

12/05/2024

Oncology

News

Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer

11/26/2024

Stephanie Holland

According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...

According to additional results...

11/26/2024

Oncology

Recent News

News

Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer

04/02/2026

Stephanie Holland

Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...

Results from a phase 2 trial...

04/02/2026

Oncology

News

Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC

04/02/2026

Stephanie Holland

Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.

Updated results from the phase 3...

04/02/2026

Oncology

News

Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC

04/02/2026

Stephanie Holland

Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.

Exploratory results from the...

04/02/2026

Oncology

FDA Approval

FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma

04/02/2026

Stephanie Holland

Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.

Based on results from the phase...

04/02/2026

Oncology

News

Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer

04/02/2026

Emily Estrada

Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.

Updated results from the phase 2...

04/02/2026

Oncology

News

Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC

04/01/2026

Emily Estrada

According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.

According to results from the...

04/01/2026

Oncology

News

Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer

04/01/2026

Stephanie Holland

Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.

Results from a phase 3 study...

04/01/2026

Oncology

News

Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer

04/01/2026

Emily Estrada

Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.

Results from the phase 2 ARC-9...

04/01/2026

Oncology

News

Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma

03/31/2026

Emily Estrada

Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.

Results from a translational...

03/31/2026

Oncology

News

Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML

03/31/2026

Emily Estrada

Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.

Results from a multicenter,...

03/31/2026

Oncology